Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder

Next Previous
Trial Profile

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Borderline personality disorders
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

  • 21 Sep 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm changed from 1 to 2
  • 08 Nov 2021 Status changed from recruiting to completed.
  • 22 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Oct 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top